Metabolites in the Tumor Microenvironment Reprogram Functions of Immune Effector Cells Through Epigenetic Modifications
Overview
Authors
Affiliations
Cellular metabolism of both cancer and immune cells in the acidic, hypoxic, and nutrient-depleted tumor microenvironment (TME) has attracted increasing attention in recent years. Accumulating evidence has shown that cancer cells in TME could outcompete immune cells for nutrients and at the same time, producing inhibitory products that suppress immune effector cell functions. Recent progress revealed that metabolites in the TME could dysregulate gene expression patterns in the differentiation, proliferation, and activation of immune effector cells by interfering with the epigenetic programs and signal transduction networks. Nevertheless, encouraging studies indicated that metabolic plasticity and heterogeneity between cancer and immune effector cells could provide us the opportunity to discover and target the metabolic vulnerabilities of cancer cells while potentiating the anti-tumor functions of immune effector cells. In this review, we will discuss the metabolic impacts on the immune effector cells in TME and explore the therapeutic opportunities for metabolically enhanced immunotherapy.
Tumor cells escape immunosurveillance by hampering LFA-1.
Upadhyay S, Murugu L, Svensson L Front Immunol. 2025; 16:1519841.
PMID: 39911389 PMC: 11794523. DOI: 10.3389/fimmu.2025.1519841.
Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies.
Jureczek J, Kalwak K, Dziegiel P Cancers (Basel). 2025; 16(24.
PMID: 39766080 PMC: 11674729. DOI: 10.3390/cancers16244181.
Changes in tumor and cardiac metabolism upon immune checkpoint.
Leven A, Wagner N, Nienaber S, Messiha D, Tasdogan A, Ugurel S Basic Res Cardiol. 2024; 120(1):133-152.
PMID: 39658699 PMC: 11790718. DOI: 10.1007/s00395-024-01092-8.
Yue B, Gao Y, Hu Y, Zhan M, Wu Y, Lu L Clin Transl Med. 2024; 14(7):e1731.
PMID: 38935536 PMC: 11210506. DOI: 10.1002/ctm2.1731.
Editorial: Tumor microenvironment and hematological malignancies: new evidences and new questions.
Fiorcari S, Strati P, Dondi E Front Immunol. 2024; 15:1407981.
PMID: 38690284 PMC: 11059779. DOI: 10.3389/fimmu.2024.1407981.